TerminatedPHASE1, PHASE2NCT01884740

Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22

Studying Anaplastic astrocytoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Weill Medical College of Cornell University
Principal Investigator
Jeffery Greenfield, MD PhD
Weill Medical College of Cornell University
Intervention
SIACI of Erbitux and Bevacizumab(drug)
Enrollment
13 enrolled
Eligibility
1-21 years · All sexes
Timeline
20132018

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01884740 on ClinicalTrials.gov

Other trials for Anaplastic astrocytoma

Additional recruiting or active studies for the same condition.

See all trials for Anaplastic astrocytoma

← Back to all trials